Maravai LifeSciences (MRVI) Q4 2024 earnings summary

Executive summary

• FY 2024 revenue was $259M, with base business revenue at $193M and high-volume CleanCap® revenue at $66M; Q4 revenue was $57M, and the year saw a net loss of $260M and adjusted EBITDA of $36M (14% margin).

• 2024 was marked by significant headwinds, including a 10.3% year-over-year revenue decline, but also by progress in strategic initiatives such as facility expansions, new product launches, and acquisitions.

• Major capital projects were completed, and partnerships and acquisitions (Officinae Bio, Molecular Assemblies) were advanced to support future growth.

• Enhanced business intelligence and customer agreements are expected to improve forecasting and clinical program visibility.

• 2025 is positioned as a reset year, focusing on innovation, operational efficiency, and strategic acquisitions.

Financial highlights

• Q4 2024 revenue was $57M; full-year revenue was $259M, at the midpoint of guidance.

• Q4 2024 GAAP net loss was $46M; full-year net loss was $260M, with adjusted EBITDA of $36M (14% margin).

• Ended 2024 with $322M in cash, $300M in long-term debt, and a $22M net cash position after a $228M voluntary debt paydown.

• Gross capital expenditures were $30M in 2024, offset by $7M in BARDA funding, for a net $23M.

• Adjusted net loss per share (non-GAAP) was $(0.10) for 2024; diluted weighted average share count was 255M for Q4 and 254M for the full year.

Outlook and guidance

• 2025 revenue guidance is $185–$205M, focused on base business, with high-volume CleanCap® revenue expected to decline.

• Q1 2025 revenue expected at $43–$45M, slightly above Q4 2024 base business.

• No adjusted EBITDA guidance for 2025, as current revenue levels are not expected to support positive adjusted EBITDA.

• Interest expense for 2025 projected at $14–$16M; depreciation/amortization at $50–$55M; equity-based compensation at $45–$50M; CapEx expected to decline to $15–$20M.

• No COVID vaccine-related revenue included in 2025 guidance.